US EditionFloodgates for Cheap Weight-Loss Drugs Open as Key Patent Expires
More than 40 Indian firms are launching generic semaglutide, with prices expected to drop 50-70%, boosting access for Type 2 diabetes and obesity patients, analysts say.
- Following the March 20 patent expiry, Indian firms including Sun Pharma, Dr Reddy's, Zydus, Lupin, Natco and Mankind began rolling out generics in India, impacting access.
- Entry of multiple local players has changed pricing and access in India’s out-of-pocket healthcare system, as more than 40 firms prepare to launch semaglutide for Type 2 diabetes and obesity.
- The locally made 15mg/3ml cartridge from Ahmedabad costs about ₹2,200, while prices are expected to fall further to ₹1,500 to ₹2,500, analysts say.
- Lower prices will expand access for many patients in India, but clinicians warn of misuse for cosmetic weight loss and emphasize prescription medical supervision due to nausea and serious risks.
- Some companies are looking beyond India for global supply, leveraging India’s manufacturing capacity for domestic and export markets, while industry estimates value the GLP-1 market at around $1 billion.
14 Articles
14 Articles
Becoming thinner just got cheaper: Weight-loss drug Semaglutide's price may drop from ₹11K to ₹3K in India
Something important has just shifted in India’s pharma space, and it directly affects people dealing with diabetes and weight concerns. A key patent around semaglutide expired on March 20, opening the market for Indian drugmakers to launch their own versions. What this really means is simple. A drug that was earlier expensive and largely controlled by global companies is now becoming more affordable and easier to access in India. And that could …
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection from his successful weight loss drug, opening the door to cheaper competing versions.
India's weight-loss drug boom: Novo Nordisk talks about GLP-1 generics after patent expiry
The patent on semaglutide, found in Novo Nordisk's Ozempic and Wegovy weight-loss drugs, expired in India on March 20. Vikrant Shrotriya, managing director at Novo Nordisk India, talks about how generics could reshape the market. He says he does expect drugs in India need an 'Indian centric' pricing to make them more accessible.
elcorreogallego.es
India's pharmaceutical industry has begun this Saturday to market its first generic versions of weight loss and diabetes drugs, just 24 hours after the Danish firm Novo Nordisk's patent on semaglutide, the base compound of popular Ozempic and Wegovy, expired.
Málaga Hoy
Granada HoyIndia launches first generic versions of weight loss and diabetes drugs
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
